Search

Displaying results 2251 - 2260 of 7503 in total
  1. Drug

    Bivalirudin

    go.drugbank.com/drugs/DB00006
    ApprovedInvestigational

    Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. … Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.

  2. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures.

  3. Drug

    Tegafur

    go.drugbank.com/drugs/DB09256
    ApprovedInvestigational

    Tegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the

  4. Drug

    Viloxazine

    go.drugbank.com/drugs/DB09185
    ApprovedInvestigationalWithdrawn

    In April 2021, an extended-release formulation of viloxazine under the brand name QELBREE was approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD).[A247985] … It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy.

  5. Drug

    Nevirapine

    go.drugbank.com/drugs/DB00238
    ApprovedInvestigational

    Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. … A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS.

    Mixtures: ZIMODINE N ®, LAVUZID® NCategories: Non-Nucleoside Reverse Transcriptase Inhibitors, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
  6. Drug

    Demecarium

    go.drugbank.com/drugs/DB00944
    Approved

    Cholinesterase inhibitors prolong the effect of acetylcholine, which is released at the neuroeffector junction of parasympathetic postganglion nerves, by inactivating the cholinesterases that break it … The outflow of the aqueous humor is facilitated, which leads to a reduction in intraocular pressure.

  7. Drug

    Exenatide

    go.drugbank.com/drugs/DB01276
    ApprovedInvestigational

    Exenatide was given FDA approval on April 28, 2005[L6106]. It is available as immediate- and extended-release formulations. … It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control[L42690].

  8. Drug

    Pork collagen

    go.drugbank.com/drugs/DB14100
    Approved

    The surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … It serves as an alternative repair treatment for patients with inadequate response to pre-existing surgical methods.

  9. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons. … [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive

  10. Drug

    Methyltestosterone

    go.drugbank.com/drugs/DB06710
    ApprovedInvestigational

    Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US.